Share Name Share Symbol Market Type Share ISIN Share Description
Port Erin LSE:PEBI London Ordinary Share IM00B6QH1J21 ORD 0.0001P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.50p -8.00% 5.75p 5.50p 6.00p 6.25p 5.75p 6.25p 25,000 14:38:44
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -0.6 -2.0 - 1.73

Port Erin (PEBI) Latest News

More Port Erin News
Port Erin Takeover Rumours

Port Erin (PEBI) Share Charts

1 Year Port Erin Chart

1 Year Port Erin Chart

1 Month Port Erin Chart

1 Month Port Erin Chart

Intraday Port Erin Chart

Intraday Port Erin Chart

Port Erin (PEBI) Discussions and Chat

Port Erin Forums and Chat

Date Time Title Posts
12/10/201619:27PORT ERIN BIOPHARMA - thread with charts125
18/7/201315:29Port Erin Biopharma Investments49

Add a New Thread

Port Erin (PEBI) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Port Erin trades in real-time

Port Erin (PEBI) Top Chat Posts

Port Erin Daily Update: Port Erin is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker PEBI. The last closing price for Port Erin was 6.25p.
Port Erin has a 4 week average price of 5.86p and a 12 week average price of 5.39p.
The 1 year high share price is 9.63p while the 1 year low share price is currently 3.55p.
There are currently 30,000,000 shares in issue and the average daily traded volume is 2,083 shares. The market capitalisation of Port Erin is £1,725,000.
rivaldo: NAV at 30/9 reported this morning at 9.96p per share, up from 9.28p: Http:// And that excludes the uplift this month from SUMM, plus any uplift from DBC's upcoming reverse into LIFE: "The Net Asset Value ("NAV") calculation for the Company as at closing on 30 September 2016 was 9.96 pence per share, including un-invested cash of GBP12,921. The portfolio is valued under IFRS at bid price. Net Assets stand at GBP2.35 million including Investments of GBP2.33 million. This quarter's NAV represents an increase of 7.33% from the previous valuation of 9.28 pence per share, which included un-invested cash of GBP11,985. No additional management fee is due to Shellbay Investments Limited. The reported NAV to 30 September 2016 gained mainly due to an increase in the value of the Magna Biopharma Fund investment. The Company's three principal investments continue to show significant growth prospects for 2016 and beyond. In particular we note the positive news from Summit Therapeutics plc ("Summit") on 4 October 2016 that it had entered into an exclusive licence and collaboration agreement with Sarepta Therapeutics for Summit's utrophin modulator pipeline."
rivaldo: FYI a poster elsewhere believes PEBI own 377,654 shares in SUMM, which would now be worth £955,000. Looks like PEBI are well undervalued at the current price assuming SUMM holds its new levels. EDIT - just noticed that the SUMM holding was worth £218,291 at 30/6/16: Http:// Since SUMM's price was around 108p at that point, that implies a holding of around 200,000 shares, i.e now worth £500,000.
rivaldo: Huge deal for SUMM this morning - and their share price is up 40%. I can't see how many shares PEBI own in SUMM anywhere. The only clue is the potentially 5.3m shares in March'13 in the thread header, which would have become around 265,000 shares post 1 for 20 consolidation. So the current SUMM stake would be worth almost £500k at the now 180p.
colin12345678: For those unaware, Port Erin Biopharma’s Net Asset Value surged overnight following some spectacular developments in its portfolio companies: • Summit Therapeutics: Its NASDAQ traded stock (SMMT) shot-up by 92% initially before settling at 52.8% following a further detailed update on the hugely significant FDA clearance. Its lead drug candidate Ezutromid, worth over £600m if commercially successful, has been granted IND status, thereby paving way for a Phase II proof-of-concept trial across the U.S. From a historical perspective, and in 69% of cases, this type of FDA clearance has often led to commercial success – hence the share price surge in New York. And as the reality continues to set-in, expect further rises to follow. • Magna Biopharma Income Fund: Over the last fortnight, the value of the fund has been substantially enhanced (24.3%) following strong rises in its Dexcom, Novartis and Lannett Co. holdings. • Regent Pacific Group: Last week, RPG announced that it has entered into a binding Term Sheet with DBC (Diabetic Boot Company) in respect of a conditional subscription for up to 130,434 new DBC shares (and 65,217 Warrants) for an aggregate consideration of up to £2,999,982. This will represent approximately 33.10% of DBC! Put simply, the company is now in full control of PulseFlow Technologies. And at the last valuation in July 2015, DBC shares (privately held) were valued at £13.37 per share. Last week, the shares were valued at £23.00; an 80.5% increase in just 9 months! The company hopes to float on NASDAQ in the short to medium term. Click the ‘download report’ for the full analysis in the GECR link below. With an updated NAV of 15.8p (and rising…), hold on to your shares; the re-rate is underway.
fastbuck: Jump on low volumes this morning before further volume and some selling was attracted. Even at 8p we are still well short of the c. 11p NBV without factoring the upside in NBV when Plethora takeover is factored in at more than twice the current share price. Guess we are looking at a resultant 12p NBV then.
rivaldo: Nice rise today, presumably in anticipation of the coming cash distribution. Good summary by a poster called casper72 elsewhere dated 28th November after the distribution RNS was issued: "I read the announcement today as essentially saying: "we will buy back shares from existing shareholders and cancel them, using money from the Magna Fund". no details on price, but its fairly easy to work out the overall picture. The Magna fund value is currently about 9.6p/PEBI share, so the distribution will, after costs, deliver equivalent value to each shareholder. Lets assume that they decide to buy back 1 share for every 2 shares owned. - you get back 9.6p/share (capital gains as its a share redemption, rather than dividend, but think of it as a dividend) - total value of PEBI drops by 9.6p/share, leaving a balance sheet value of 5.8p remaining, half of this being holdings in listed shares, half unlisted - the shares in issue halve from today, so the net asset value per share doubles back up to 11.6p/share That means that the market is effectively discounting the remaining PEBI investments by 80% (difference between current offer of 10.5p share and the 9.6p distribution = 0.9p, vs. balance sheet value of 5.8p/share prior to share redemption). This seems like a material discount to me. The only complication will be the fact that PEBI will be so small at the end of this process that I don't think that it will be economically viable in the long run (would only have a market cap of £1.8m). Welcome views on the maths and other risks - I flagged that this was a good opportunity a while back - seems to be even more so now. "
trentendboy: Strong move today. This new policy should work to close the discount to nav. Ant company news I have missed? You would think so from the share price move. Missed a top up at 10 though
rivaldo: ARWR's share price has galloped ahead and is now $12.66, compared to the $4.80 in the thread header post: Http://;range=6m;compare=;indicator=volume;charttype=area;crosshair=on;ohlcvalues=0;logscale=off;source=undefined; This is now worth around £1.3m assuming PEBI haven't sold any, and means that along with PLE and SUMM the company now has three major shareholdings worth (without using a calculator!) around £3m between them without taking any of the other holdings into account. I note that SGYP is also up to $5.74, against $4.81 in the header, and NKTR is nicely up too.
rivaldo: Hi tightfist. Do you keep track of all the holdings in the thread header post on your spreadsheet? Quite a task (unless automated I suppose)! Let's hope PEBI did buy more PLE as you say. It's PLE, SUMM and ARWR which will drive PEBI's share price unless something else comes up on the rails (I'm very, very optimistic about APHB).
rivaldo: This PEBI thread is partly due to its stake in Ampliphi Biosciences (APHB), in which I have a holding. The APHB thread is here: PEBI's m/cap with 33.86m shares in issue is £2.37m at 7p. At 30th June 2013 PEBI had £3.6m net assets, or 10.6p per share, comprising £2.92m of investments and £0.7m of uninvested cash. Largest investments at 30th June 2013: Synergy Pharmaceuticals Inc. 277,748 9.52% (plus £10k of warrants in 2012) Summit Corporation plc 212,500 7.29% (when share price was around 4p, 15p at 20/9/13) Arrowhead Research (ARWR) 207,364 7.11% (when share price was around $2, now $4.75) Plethora Solutions Holdings 166,625 5.71% (when share price was around 2p, now 13p) TrovaGene Inc. 137,224 4.70% Pfizer Inc. 136,562 4.68% Nektar Therapeutics 127,303 4.36% Sanofi-ADR 91,349 3.13% 1,356,675 46.51% Plus Ampliphi Biosciences (APHB) 60,000 (when share price was around 15c, now 55c). From the above, shareholdings must be approximately: SUMM : 5,300,000 shares @ 19.25p = £1.03m PLE : 8,300,000 shares @ 14.2p = £1.18m APHB : 500,000 shares @ $0.55 = £0.2m ARWR : 160,000 shares @ $4.80 = £0.5m SGYP : 108,000 shares @ $4.81 = £0.35m TROV : 36,000 shares @ $7.00 = £0.15m NKTR : 17,000 shares @ $10.40 = £0.1m Links to share prices: PLE : SUMM : APHB : ARWR : SGYP : TROV : NKTR : Quote for Magna Biopharma Fund: Http:// An info sheet from the 2012 Master Investor show lists the following additional holdings totalling approx. £1.55m: Novartis : £156,000 Astellas Pharma : £134,000 Abbot Labs : £111,000 Merck : £91,000 Onyx Pharma : £86,000 H Lundebeck : £73,000 Immunocellar Therapeutics : £68k Celgene : £68,000 Map Pharmaceuticals : £68,000 Eli Lilly : £67,000 Medivir : £66,000 Shire : £66,000 Rigel Pharmaceutical : £64,000 Polymedix : £54,000 Pharmathene : £52,000 Medivation : £51,000 Siga Technologies : £49,000 Sundry other holdings : £214,000, incl Miraculins, Synta, Spiritus, Pacific Biosciences, Biotime, Methylgene, Complete Genomics Here's an old 23 minute interview with Jim Mellon re PEBI which notes that it has 20 holdings. He mentions Medivation, which has increased from $52 at 30/6 to $57.50 now: Disclosure : I've held shares in PEBI since just before I opened this thread.
Port Erin share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V: D:20161022 23:44:02